Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts

Leukemia Research

Volumn 33, Issue 11, 2009, Pages 1469-1474

  Cermak, Jaroslav ^a   Kacirkova, Petra ^a   Mikulenkova, Dana ^a   Michalova, Kyra ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Iron overload; Myelodysplasia; Prognosis; Survival; Transfusion; WPSS

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DEFERIPRONE; FERRITIN; HEMOGLOBIN;

ADULT; ARTICLE; CHELATION THERAPY; DISEASE COURSE; DYSPLASIA; EARLY CANCER; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDEPENDENT VARIABLE; IRON OVERLOAD; KARYOTYPE; LEUKEMIA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; UNIVARIATE ANALYSIS;

BLOOD TRANSFUSION; HUMANS; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS;

EID: 68649124372     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.033     Document Type: Article

References (27)

1. Bowen D.T., and Hellström-Lindberg E. Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?. Leuk Res 25 (2001) 19-21
2. Malcovati L., Della Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for decision making. J Clin Oncol 23 (2005) 7594-7603
3. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndrome. J Clin Oncol 25 (2007) 3503-3510
4. Konen E., Ghoti H., Goitein O., Goitein O., Winder A., Kushnir T., et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol 82 (2007) 1013-1016
5. Chacko J., Pennell D.J., Tanner M.A., Hamblin T.J., Wonke B., Levy T., et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 138 (2007) 587-593
6. Di Tucci A., Matta G., Deplano S., Gabbas A., Depau C., Derudas D., et al. Myocardial iron overload assessment by t2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 93 (2008) 1385-1388
7. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vradiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3839
8. Greenberg P., Cox C., Le Beau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
9. Sanz G., Nomdeden B., Such E., Bernal T., Belkaid M., Ardanaz M.T., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome (abstr.). Blood 112 (2008) 238
10. Čermák J., Michalová K., Březinová J., and Zemanová Z. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q-syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res 27 (2003) 221-229
11. Kantarjian H., Brien O., Ravandi S., Cortes F., Shan J., Bennett J.M., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts that accounts for events not considered in the original international prognostic scoring system. Cancer 113 (2008) 1351-1361
12. Porter J.B. Practical management of iron overload. Br J Haematol 115 (2001) 239-252
13. Anderson L.J., Holden S., Davis B., Prescott E., Charrier C.C., Bunce N., et al. Cardiovascular T2 star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22 (2001) 2171-2179
14. St Pierre T.G., Clark P.R., Chua-anusorn W., Fleming A.J., Jeffrey G.P., Olynyk J.K., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 (2005) 855-861
15. Telfer P.T., Prescott E., Holden S., Walker M., Hoffbrand A.V., and Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalasemia major. Br J Haematol 110 (2000) 971-977
16. Jensen P.D., Jensen F.T., Christensen T., Eiskjaer H., Baandrup U., and Nielsen J.L. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 101 (2003) 4632-4639
17. Olivieri N.F., Nathan D.G., MacMillan J.H., Wayne A.S., Liu P.P., McGee A., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331 (1994) 574-578
18. Taher A., Nathan D., and Porter J. Evaluation of iron levels to avoid the clinical sequelae of iron overload. Semin Hematol 44 (2007) S2-S6
19. Schafer A.I., Cheron R.G., Dluhy R., Cooper B., Gleason R.E., Soeldner J.S., and Bunn H.F. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304 (1981) 319-324
20. Garcia-Manero G., Shan J., Faderl S., Cortes J., Ravandi F., Borthakur G., et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22 (2008) 538-543
21. Oliva E.N., Dimitrov B.D., Benedetto F., D Angelo A.D., and Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 29 (2005) 1217-1219
22. Goldberg S.L. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res 31 Suppl. 3 (2007) S16-S22
23. Buja L.M., and Roberts W.C. Iron in the heart. Am J Med 51 (1971) 209-221
24. Porter J.B., Tanner M.A., Pennell D.J., and Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferiprone) (abstr.). Blood (2005) 106 abstr.3600
25. Leitch H.A. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 31 Suppl. 3 (2007) S7-S9
26. Rose C., Brechignac S., Vassilief D., Beyne-Rauzy O., Stamatoullas A., Larbaa D., et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM (abstr.). Blood (2007) 110 abstr. 249
27. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83 (2008) 858-861